Reports
Reports
Sale
The global lancet market size was valued at USD 2 billion in 2023, driven by the increasing availability of a big pool of diabetic patients. The market size is anticipated to grow at a CAGR of 10.6% during the forecast period of 2024-2032 to achieve a value of USD 4.9 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The lancet is a small medical implement used to prick the skin, particularly for blood sugar monitoring or capillary blood sampling. The growth of the lancet market can be attributed to the availability of a big pool of diabetic patients and the growing incidences of infectious diseases requiring blood testing for diagnosis and therapy, along with increased awareness of diabetes treatment globally.
Rising Prevalence of Diabetes and High Cholesterol
The increasing issue of high cholesterol among people, especially the geriatric population, is contributing to the global lancet market demand. It is estimated that high cholesterol causes 4.4 million deaths every year. It is a major risk factor for heart disease and stroke in both high- and low-income countries. Practices such as consuming a healthy diet, regular exercise, and medication can help reduce high cholesterol.
In June 2023, according to data from the Institute for Health and Metrics Evaluation, over 500 million people across the globe are currently living with diabetes. This chronic disease affects individuals of all ages and genders in every country worldwide. Unfortunately, this number is projected to more than double in the next 30 years, with estimates suggesting that 1.3 billion people will be living with diabetes by then. This increase is expected to be experienced in every country, highlighting the urgent need for effective prevention and management strategies.
The high prevalence of such conditions requires regular checkups so that they can be diagnosed early and treated well. The lancet are used in the devices that are used to diagnose these conditions through blood sampling such as cholesterol testing devices.
Increased Product Launches in the Market
In August 2023, Roche Diabetes Care Japan Co., Ltd. announced the launch of Accu-Chek Pico, a handy and fully disposable lancet device for blood glucose monitoring to enhance diabetes care for older people living with diabetes nationwide. Accu-Chek Pico will be available in medical institutions such as hospitals and retail pharmacies across Japan.
This innovative product, designed for older people with diabetes is poised to enhance diabetes care. Further, the availability in medical institutions and retail pharmacies throughout Japan for this product is expected to potentially increase demand for lancet in the region, bolstering the lancet market growth.
Additionally, in January 2024, Dexcom revealed new details about Stelo, its new continuous glucose monitor (CGM) designed for people with diabetes who do not take insulin. Stelo by Dexcom, a new continuous glucose monitor targeted for people with diabetes who are not on insulin, has been submitted to the FDA. The medical equipment manufacturer also shared updates on the unique features of the wearable, pricing, and the planned rollout timeline for the device. Stelo launch is expected this summer of 2024 if approved successfully.
This may impact the lancet market potentially by reducing the demand for traditional blood glucose monitoring using lancet. CGMs like Stelo offer continuous monitoring without the need for frequent fingerstick tests which may potentially lead to a shift in user preferences and impact the market for lancet used in traditional blood glucose meters.
Rapid Improvements to Provide a Significant Push
In November 2023, Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus on lung disease, announced the validation and launch of a new method of collecting blood specimens for Nodify Lung Nodule Risk Assessment testing. The method uses the FDA-cleared Tasso+™ device, a single-use blood lancing device intended for obtaining capillary whole blood samples from a patient’s upper arm.
The integration of innovative devices like Tasso+™ signals potential growth, as it introduces an efficient and patient-friendly alternative for fetching blood samples, potentially influencing increased adoption and demand in the lancet market.
Increase in FDA Approvals
In October 2023, Sanguina received the approval from the US Food and Drug Administration (FDA) for its haemoglobin test kit, AnemoCheck Home. AnemoCheck Home, which is an in vitro diagnostic device, will be available only through prescription. Sanguina’s disposable test helps users receive precise haemoglobin level readings by carrying out a simple fingerstick blood test. Sanguina is focused on the development of digital and at-home health platforms for quick home-based testing and disease management. The brand is excited to provide a convenient, accurate, and accessible tool to monitor their haemoglobin levels at home. This approval would significantly aid the global lancet market demand as the test requires a simple fingerstick blood sample, propelling the demand for lancets used in home-based testing and aligning with the growing trend of at-home health monitoring and disease management. Globally, around 40% of all children aged 6–59 months, 37% of pregnant women, and 30% of women 15–49 years of age are affected by anaemia.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Type
Market Breakup by Applications
Market Breakup by End User
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The growth of the market is primarily driven by the increasing incidences of diabetes and high infectious diseases worldwide. However, the danger of needlestick injuries, the reuse of lancets, and the bad reimbursement situation may act as the major market constraints, hampering the lancet market growth.
North America is anticipated to dominate the regional market due to factors such as the increasing healthcare sector, increasing geriatric population, fast financial development, and increased awareness of diabetes treatment are some of the primary factors, which are aiding in the growth of the North America lancet market growth.
In January 2023, Cipla launched a point-of-care testing device for various non-communicable diseases and other medical conditions. Another addition to its product offerings for diagnostics laboratories, Cipla’s device named Cippoint, offers a wide range of testing parameters including cardiac markers, diabetes, infectious diseases, fertility, thyroid function, inflammation, metabolic markers, and coagulation markers. The device is approved by the European In-Vitro Diagnostic Device Directive, thus ensuring reliable testing solutions.
Cippoint – an immunofluorescence-based quantitative analyser, can help healthcare professionals to get test results in 3 to 15 minutes, thus enabling a faster clinical decision-making process.
The introduction of Cipla's point-of-care testing device could increase the demand for lancets as they are commonly used in devices for blood sampling in point-of-care diagnostics, bolstering the market demand. The focus of Cippoint on accessibility in rural and remote areas is further expected to drive the need for lancets in healthcare settings.
In December 2023, BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced it had received 510(k) clearances from the U.S. Federal Drug Administration (FDA) for a novel blood collection device that obtains blood samples from a fingerstick that produce lab-quality results for some of the most commonly ordered blood tests.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Type |
|
Breakup by Applications |
|
Breakup by End User |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Lancet Market Overview
3.1 Global Lancet Market Historical Value (2017-2023)
3.2 Global Lancet Market Forecast Value (2024-2032)
4 Global Lancet Market Landscape
4.1 Global Lancet Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Lancet Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Applications
5 Global Lancet Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Lancet Market Segmentation (2017-2032)
6.1 Global Lancet Market (2017-2032) by Type
6.1.1 Market Overview
6.1.2 Safety Lancet
6.1.2.1 Side Button Lancet
6.1.2.2 Push Button Safety Lancet
6.1.2.3 Pressure Activated Safety Lancet
6.1.3 Personal Lancet
6.2 Global Lancet Market (2017-2032) by Applications
6.2.1 Market Overview
6.2.2 Hemoglobin Testing
6.2.3 Glucose Testing
6.2.4 Coagulation Testing
6.2.5 Others
6.3 Global Lancet Market, by End User
6.3.1 Market Overview
6.3.2 Hospitals and Clinics
6.3.3 Diagnostics Centers and Pathology Laboratories
6.3.4 Home Diagnostics
6.3.5 Research and Academic Laboratories
6.4 Global Lancet Market (2017-2032) by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Lancet Market (2017-2032)
7.1 North America Lancet Market (2017-2032) by Type
7.1.1 Market Overview
7.1.2 Safety Lancet
7.1.2.1 Side Button Lancet
7.1.2.2 Push Button Safety Lancet
7.1.2.3 Pressure Activated Safety Lancet
7.1.3 Personal Lancet
7.2 North America Lancet Market (2017-2032) by Application
7.2.1 Market Overview
7.2.2 Hemoglobin Testing
7.2.3 Glucose Testing
7.2.4 Coagulation Testing
7.2.5 Others
7.3 North America Lancet Market (2017-2032) by Country
7.3.1 United States of America
7.3.2 Canada
8 Europe Lancet Market (2017-2032)
8.1 Europe Lancet Market (2017-2032) by Type
8.1.1 Market Overview
8.1.2 Safety Lancet
8.1.2.1 Side Button Lancet
8.1.2.2 Push Button Safety Lancet
8.1.2.3 Pressure Activated Safety Lancet
8.1.3 Personal Lancet
8.2 Europe Lancet Market (2017-2032) by Application
8.2.1 Market Overview
8.2.2 Hemoglobin Testing
8.2.3 Glucose Testing
8.2.4 Coagulation Testing
8.2.5 Others
8.3 Europe Lancet Market (2017-2032) by Country
8.3.1 United Kingdom
8.3.2 Germany
8.3.3 France
8.3.4 Italy
8.3.5 Others
9 Asia Pacific Lancet Market (2017-2032)
9.1 Asia Pacific Lancet Market (2017-2032) by Type
9.1.1 Market Overview
9.1.2 Safety Lancet
9.1.2.1 Side Button Lancet
9.1.2.2 Push Button Safety Lancet
9.1.2.3 Pressure Activated Safety Lancet
9.1.3 Personal Lancet
9.2 Asia Pacific Lancet Market (2017-2032) by Application
9.2.1 Market Overview
9.2.2 Hemoglobin Testing
9.2.3 Glucose Testing
9.2.4 Coagulation Testing
9.2.5 Others
9.3 Asia Pacific Lancet Market (2017-2032) by Country
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 Australia
9.3.5 ASEAN
9.3.6 Others
10 Latin America Lancet Market (2017-2032)
10.1 Latin America Lancet Market (2017-2032) by Type
10.1.1 Market Overview
10.1.2 Safety Lancet
10.1.2.1 Side Button Lancet
10.1.2.2 Push Button Safety Lancet
10.1.2.3 Pressure Activated Safety Lancet
10.1.3 Personal Lancet
10.2 Latin America Lancet Market (2017-2032) by Application
10.2.1 Market Overview
10.3 Latin America Lancet Market (2017-2032) by Country
10.3.1 Brazil
10.3.2 Argentina
10.3.3 Mexico
10.3.4 Others
11 Middle East and Africa Lancet Market (2017-2032)
11.1 Middle East and Africa Lancet Market (2017-2032) by Type
11.1.1 Market Overview
11.1.2 Safety Lancet
11.1.2.1 Side Button Lancet
11.1.2.2 Push Button Safety Lancet
11.1.2.3 Pressure Activated Safety Lancet
11.1.3 Personal Lancet
11.2 Middle East and Africa Lancet Market (2017-2032) by Application
11.2.1 Market Overview
11.2.2 Hemoglobin Testing
11.2.3 Glucose Testing
11.2.4 Coagulation Testing
11.2.5 Others
11.3 Middle East and Africa Lancet Market (2017-2032) by Country
11.3.1 Saudi Arabia
11.3.2 United Arab Emirates
11.3.3 Nigeria
11.3.4 South Africa
11.3.5 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by NIH Departments
14.7 Analysis by Recipient Organization
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 Terumo Corporation
17.1.1 Company Overview
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Bayer AG
17.2.1 Company Overview
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 MTD Medical technology and Devices
17.3.1 Company Overview
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Sarstedt AG & Co. KG
17.4.1 Company Overview
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 BD
17.5.1 Company Overview
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Abbott
17.6.1 Company Overview
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 F. Hoffmann-La Roche Ltd.
17.7.1 Company Overview
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Greiner Bio-One International GmbH
17.8.1 Company Overview
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Improve Medical
17.9.1 Company Overview
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 B. Braun SE
17.10.1 Company Overview
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Medline Industries, Inc.
17.11.1 Company Overview
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Nipro Medical Corporation
17.12.1 Company Overview
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Owen Mumford
17.13.1 Company Overview
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 ARKRAY, Inc.
17.14.1 Company Overview
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 Bionime Corporation
17.15.1 Company Overview
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
List not exhaustive
18 Global Lancet Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
The market attained a value of about USD 2 billion in 2023, driven by the increasing prevalence of diabetes and anemia.
The market is anticipated to grow at a CAGR of 10.6% during the forecast period of 2024-2032 and is likely to reach a market value of USD 4.9 billion by 2032.
Factors such as the increasing prevalence of anemia, high cholesterol, and diabetes among people, market expansion with product launches, and technological advancements are among the major factors driving the market demand.
The increasing number of FDA clearances for new devices is a major trend influencing the market growth.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is currently leading the global market.
The types of lancets can be divided into side button lancets and personal lancet. Side button lancets can be divided into push button safety lancets, and pressure-activated safety lancet.
Lancets have wide applications in hemoglobin testing, glucose testing, and coagulation testing, among others.
End users in the market are hospitals, clinics, diagnostics centers, pathology laboratories, home diagnostics, research, and academic laboratories.
Key players involved in the market are Terumo Corporation, Bayer AG, MTD Medical Technology and Devices, Sarstedt AG & Co. KG, BD, Abbott, F. Hoffmann-La Roche Ltd., Greiner Bio-One International GmbH, Improve Medical, B. Braun SE, Medline Industries, Inc., Nipro Medical Corporation, Owen Mumford, ARKRAY, Inc., and Bionime Corporation.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.